Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

Inizio, a commercialization partner for health and life science companies, has today announced the appointment of Colin Stanley as ...

Sage Therapeutics, Inc. ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board intends to evaluate ...

Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, and Innovation Zed, a pioneering developer of connected add-on devices ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Biogen Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sage has seen a series of trial setbacks in 2024, including its decision to discontinue development of one of its neurological drugs after a third trial failure. Vertex Pharmaceuticals Inc ...